Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/Philippines FDA/Uptravi

Approved

STANDARD

Uptravi

Excella GmbH & Co. KG🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: c877b697e8f4d907
Company: Excella GmbH & Co. KG
Type: Standard

Approval Details

Approval Id: c877b697e8f4d907
Drug Approval Philippines Name: Uptravi
Product Name: Uptravi
Registration Number: DR-XY47389
Brand Name: Uptravi
Generic Name: Selexipag
Dosage Form: Film-Coated Tablet
Dosage Strength: 200 mcg
Manufacturer: Excella GmbH & Co. KG
Importer: Johnson & Johnson (Philippines), Inc.
Company Detail Path: /organization/excella-gmbh-and-co-kg
Issuance Date: 14 May 2025
Expiry Date: 20 September 2029
Pharmacologic Category: Antithrombotic Agent
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

c877b697e8f4d907

Type

Standard

Back to Philippines FDA Approvals

Uptravi - Philippines FDA Drug Approval Details